|
Basic Characteristics of Mutations
|
|
Mutation Site
|
D215G |
|
Mutation Site Sentence
|
Individual mutations rarely increased ACE2 binding, however, several including DeltaH69V70, D215G, D614G, and H655Y achieved statistical significance (Figure S1C). |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
S |
|
Standardized Encoding Gene
|
S
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Cell line
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
- |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
39657661
|
|
Title
|
Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity
|
|
Author
|
Roederer AL,Cao Y,St Denis K,Sheehan ML,Li CJ,Lam EC,Gregory DJ,Poznansky MC,Iafrate AJ,Canaday DH,Gravenstein S,Garcia-Beltran WF,Balazs AB
|
|
Journal
|
Cell reports. Medicine
|
|
Journal Info
|
2024 Dec 17;5(12):101850
|
|
Abstract
|
With the onset of the COVID-19 pandemic 4 years ago, viral sequencing continues to document numerous individual mutations in the viral spike protein across many variants. To determine the ability of vaccine-mediated humoral immunity to combat continued SARS-CoV-2 evolution, we construct a comprehensive panel of pseudoviruses harboring each individual mutation spanning 4 years of the pandemic to understand the fitness cost and resistance benefits of each. These efforts identify numerous mutations that escape from vaccine-induced humoral immunity. Across 50 variants and 131 mutants we construct, we observe progressive loss of neutralization across variants, irrespective of vaccine doses, as well as increasing infectivity and ACE2 binding. Importantly, the recent XBB.1.5 booster significantly increases titers against most variants but not JN.1, KP.2, or KP.3. These findings demonstrate that variants continue to evade updated mRNA vaccines, highlighting the need for different approaches to control SARS-CoV-2 transmission.
|
|
Sequence Data
|
-
|
|
|